AstraZeneca 2025 Earnings and Global Expansion

AstraZeneca reported a significant 45% increase in net profit to $10.2 billion and a 9% rise in revenue to $58.7 billion for 2025, primarily driven by strong cancer drug sales. CEO Pascal Soriot expressed confidence in achieving $80 billion in annual revenue by 2030. The company is strategically expanding its presence in its two largest markets, the United States and China. AstraZeneca plans to invest $15 billion in China through 2030 for manufacturing and research, and has partnered with CSPC Pharmaceutical Group for weight-loss injections. In the United States, it intends to invest $50 billion by 2030 in manufacturing and research, partly in response to potential pharmaceutical tariffs from Donald Trump, with whom it also negotiated lower drug prices in exchange for a tariff delay. AstraZeneca also began listing its shares directly on the New York Stock Exchange to attract more investors, while maintaining its headquarters and primary listing in the United Kingdom.